RxDoctor Payments Data

Ahmed Sharaan

Pulmonary Disease · Fort Wayne, INNPI 1386183614

Payments from drug & device makers

$8,361in general payments, 2019–2025

Across 42 payments — averaging $199.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$7K
  • Boehringer Ingelheim$302
  • Mallinckrodt Hospital Products Inc.$138
  • Actelion Pharmaceuticals US, Inc.$132
  • AstraZeneca$101
  • United Therapeutics Corporation$99
  • plus $296 from 9 others

What the payments were for

  • Travel & lodging$1,19614%
  • Food & beverage$1,05513%
  • Education$6,11073%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,361 in reported general payments places this provider in the 70th percentile of 258 pulmonary disease providers in Indiana.

See all pulmonary disease providers in Indiana

Medicare billing

Part B allowed, 2024
$72,728
Medicare patients
331
Services billed
923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate70$899,833
Trelegy ElliptaFluticasone/Umeclidin/Vilanter312$260,788
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr173$101,260
Dupixent PenDupilumab16$61,536
Breo ElliptaFluticasone/Vilanterol109$53,320
Spiriva RespimatTiotropium Bromide97$52,752
Stiolto RespimatTiotropium Br/Olodaterol Hcl47$32,423
SymbicortBudesonide/Formoterol Fumarate39$12,756
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,714
Fluticasone-SalmeterolFluticasone Propion/Salmeterol49$5,794
Albuterol Sulfate HfaAlbuterol Sulfate168$4,479
DuleraMometasone/Formoterol11$3,885
Arnuity ElliptaFluticasone Furoate16$3,551
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate18$2,565
Varenicline Tartrate11$1,423

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$302$985,008214 claims
AstraZenecaSymbicort, Breztri Aerosphere$101$20,47051 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 258 pulmonary disease providers in Indiana.

Other pulmonary disease in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →